×

img Acces sibility Controls

Research Projects Banner

Research Projects

Design and Synthesis of Novel Carboline-Nucleosides with Potential Viral RdRp Inhibitor Activity: Development of Broad-Spectrum Antivirals Against RNA Viruses

Implementing Organization

National Institute of Pharmaceutical Education and Research (NIPER), Kolkata
Principal Investigator
Dr. Subhendu Bhowmik
National Institute of Pharmaceutical Education and Research (NIPER), Kolkata
CO-Principal Investigator
Dr. Anup Mazumder
National Institute of Biomedical Genomics (NIBMG), West Bengal

Project Overview

Nucleoside/tide modification is a crucial area in synthetic biology and drug discovery, with modified nucleosides being used as therapeutics and biological probes against various life-threatening diseases, including viral infections. Nucleoside analogues target viral nucleic acid replication, which is crucial in regulating viral replication. However, misincorporation or mismatch of nucleotides can cause dysfunction of viral RdRps. Nucleoside-analogues exploit this misincorporation mechanism to control viral replication. The emergence of resistance against current antiviral therapeutics is a concern, and the development of newer antiviral RdRp inhibitors with improved pharmacological profiles is urgently needed. A new class of nucleoside analogues, such as carboline nucleosides, could be a compelling alternative to current antiviral nucleosides. Carboline is the basic scaffold in several drugs and natural products, and carboline heterocycles contain pyridine and indole moiety nucleobases. A novel synthetic route has been developed to construct carboline nucleosides, which have been docked against SARS-CoV-2 RdRp and shown promising results compared to Favipiravir. The researchers plan to extend the scope of the nucleosides by validating efficacy against SARS-CoV-2 RdRp and test the molecules against other RNA viruses, such as dengue virus, to develop broad-spectrum antivirals against RNA viruses.
Funding Organization
Funding Organization
Science and Engineering Research Board (SERB), New Delhi
Anusandhan National Research Foundation (ANRF)
Quick Information
Area of Research
Pharmaceutical Sciences
Start Year
2023
End Year
2026
Sanction Amount
₹ 46.28 L
Status
Ongoing
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
N/A
Startup (If Any)
00
No. of Patents
Filed :01
Grant :00
arrowtop